
Peptide Compounding Policy in 2026: What FDA Sent to the White House, What the PCAC Voted, and What's Still Not Legal
If you prescribe or compound peptides — or you're weighing whether to add a peptide service line — the past few months have probably felt like whiplash. In July, an FDA advisory committee voted to recommend six peptides for the compounding bulks list, over the objections of the agency's own scientists. In August, the FDA was sending warning letters to online peptide sellers. And in mid-October, the agency submitted an "interim access policy" to the White House for review.
Most of what circulates online about these events gets the legal bottom line wrong. A committee vote is not an approval, and a policy sitting in White House review is not a rule. This guide separates what actually happened from what people are hoping it means, and lays out what still carries real enforcement risk for your license.
Quick answer
None of the six recommended peptides is legally compoundable under the 503A Bulks List today. The Pharmacy Compounding Advisory Committee recommended six of seven peptides for the 503A Bulks List in July, and FDA submitted an interim access policy to OIRA on October 14, 2026 — but neither step changes what a pharmacy may lawfully compound. None of these peptides is FDA-approved, none has been added to the bulks list, and FDA has not issued a final rule.

What FDA sent to the White House (and what we still don't know)
On October 14, 2026, the Office of Information and Regulatory Affairs (OIRA) — the White House office that reviews proposed regulations — received FDA's "Interim Access Policy for Compounding Using Certain Peptides." Law firm Buchanan Ingersoll & Rooney, which tracks this filing, confirms the submission is listed as pending review and carries a Regulatory Identification Number (RIN 0910-ZD94, per physician advocacy group Doctors for America, which separately identified the filing).
The most important detail is what the record does not contain. According to the OIRA filing as described by Buchanan Ingersoll & Rooney, the action is listed as a "notice" with no legal deadline, and it does not disclose the policy's text, which substances it covers, or what conditions it might attach. Reuters reported on October 15 that the filing "does not provide any details of the policy," though the Associated Press, citing two people familiar with the matter, said it would allow pharmacies to make some popular peptides including BPC-157.
In other words: a policy has reached White House review, but no one outside the agency knows yet whether it will be broad or narrow, which peptides it names, or what a pharmacy would have to do to qualify. Buchanan Ingersoll & Rooney put the operating consequence plainly: "Neither a favorable advisory recommendation nor submission of a policy for executive review independently supplies a new basis for compounding."
What the PCAC actually voted in July
The advisory committee step that set all this in motion happened July 23–24, 2026, when the FDA's Pharmacy Compounding Advisory Committee (PCAC) met at the agency's White Oak campus to consider seven peptide bulk drug substances for the 503A Bulks List — the list that determines which substances a 503A compounding pharmacy may prepare against an individual prescription. Each substance was considered in two forms, free base and acetate, under public docket FDA-2025-N-6895.
The committee recommended six of the seven, in a string of narrow votes that went against the position of FDA's own review staff. According to AJMC, BPC-157, KPV, and TB-500 each cleared 8–6 with one abstention, and MOTS-c passed 7–5 with two abstentions; Semax and Epitalon cleared the following day "by similarly tight margins." Emideltide (also called delta sleep-inducing peptide, or DSIP) was the lone rejection, voted down 7–6 with one abstention. FDA staff's briefing materials had recommended against adding any of the seven.
Peptide | Use FDA reviewed | PCAC outcome | FDA staff position |
|---|---|---|---|
BPC-157 | Ulcerative colitis | Recommended (8–6, 1 abstention) | Against listing |
KPV | Wound healing, inflammatory conditions | Recommended (8–6, 1 abstention) | Against listing |
TB-500 | Wound healing | Recommended (8–6, 1 abstention) | Against listing |
MOTS-c | Obesity and osteoporosis | Recommended (7–5, 2 abstentions) | Against listing |
Semax | Cerebral ischemia, migraine, trigeminal neuralgia | Recommended (tight margin) | Against listing |
Epitalon | Insomnia | Recommended (tight margin) | Against listing |
Emideltide (DSIP) | Opioid withdrawal, chronic insomnia, narcolepsy | Not recommended (7–6, 1 abstention) | Against listing |
Table sources: FDA PCAC meeting page (uses reviewed); AJMC (vote outcomes and FDA staff position). AJMC did not publish exact Semax and Epitalon tallies, describing them only as clearing "by similarly tight margins."
Two things about that table deserve attention. First, the "use FDA reviewed" column is what the agency evaluated the substance against — not an endorsement of that use. Second, every favorable vote was a recommendation about list placement, not about safety, dosing, or indication.

"Recommended" is not "legal" — the gap between a vote and a rule
This is where most of the confusion lives. A PCAC vote is advisory. The FDA's own meeting materials state that advisory committees make "non-binding recommendations to the FDA, which generally follows the recommendations but is not legally bound to do so."
AJMC reported that none of the six peptides has been added to the 503A Bulks List, and none is an FDA-approved drug. For a recommended substance to actually become compoundable, FDA would need to accept the committee's advice and then complete notice-and-comment rulemaking — a proposed rule, a public comment period, and a final rule. Scott Brunner, CEO of the Alliance for Pharmacy Compounding, told AJMC that FDA still must formally adopt the advisers' recommendations before the peptides may be legally compounded.
So the legal position today, before any of that happens: none of these peptides has been added to the 503A Bulks List, and none is FDA-approved for any indication. Selling or prescribing them as if they were cleared carries the same risk it did before the July meeting.
Enforcement didn't pause while the policy moved
The interim-policy submission is not the only signal FDA sent this fall. It is happening alongside active enforcement against unapproved peptides.
On August 24, 2026, FDA's Center for Drug Evaluation and Research sent a warning letter to NuScience Peptides LLC, a North Carolina company, covering nine products — including "GLP-1 Sema Research Peptide," "Tesamorelin Research Peptide," and "Bacteriostatic water for Peptides (BAC Water)" — as unapproved new drugs. The letter is notable for how directly it rejects the "research use only" framing. The agency treats the products as drugs because they are intended to diagnose, treat, or affect the structure or function of the body, and it treats the bacteriostatic water as a drug because it is sold to reconstitute injectable peptides. The letter states:
"These products are especially concerning from a public health perspective because injectable drug products can pose risks of serious harm to users. Injectable products are delivered directly into the body, sometimes directly into the bloodstream, and therefore, bypass some of the body's key defenses against toxins and microorganisms that can lead to serious and life-threatening conditions."
McDermott Will & Emery, a law firm tracking the enforcement wave, reports that FDA issued similar warning letters in August to four other online sellers — Royal Peptides, Peptide Partners, Peak Performance Peptides, and Tex Peptides. The firm notes these letters targeted substances like tesamorelin and ipamorelin and did not reference the six peptides the PCAC recommended, underscoring that enforcement is continuing even as the policy question remains open.
Enforcement is also reaching the criminal and state levels. McDermott describes the July 2026 sentencing of Matthew Kawa of Paradigm Peptides to 70 months in federal prison for introducing unapproved drugs into interstate commerce with intent to defraud, with a $5 million forfeiture and a 16-month sentence for a co-defendant. And state boards are moving too: a June 2026 Alabama Medical Board notice states a physician may not "compound, administer, or dispense a non-FDA approved or research grade peptide to a patient," and an Ohio Board of Pharmacy guidance says "for research purposes only" products are unlawful for prescriber clinics and med spas to possess regardless of patient consent.
What telehealth is signaling
The commercial stakes explain why the policy matters. Hims & Hers told investors in August that it plans a phased peptide rollout: a first group of already-permitted peptides (including sermorelin and glutathione) by the end of 2026, then the six "wellness" peptides the PCAC recommended, pending final FDA rulemaking. CEO Andrew Dudum told the company's earnings call it is "waiting on full and final rulemaking from the FDA" before launching those six, and described the peptide offering it is developing as including U.S.-manufactured products, clinical-led guidance and ongoing blood testing, according to Becker's Hospital Review.
The relevant point for a clinician is not what Hims does — it's that a large, well-capitalized telehealth platform is publicly treating final rulemaking, not the advisory vote, as the gate. That is the correct read of the law, and it is worth matching in your own planning.
What this means for your practice
For a licensed clinician deciding whether to build a peptide line, the near-term answer is unchanged from a year ago: verify legality before you prescribe, and treat any "it's basically legal now" claim as unproven.
Watch for misinformation: The most common error is treating the July PCAC vote as if it legalized BPC-157 or TB-500. It did not. Neither did the October OIRA submission. If a vendor, a telehealth recruiter, or a marketing email tells you a peptide is now legal to prescribe because "the FDA committee approved it," that statement is false on its face — the committee recommends list placement; it does not approve a drug.
What this means for you: The direction of travel is real — an interim access policy is the clearest signal yet that FDA may loosen the federal posture on these six peptides. But a signal is not a license. Here is a working checklist while the policy is still pending:
Confirm the substance's actual legal status. Check whether the peptide is on the 503A Bulks List or is an FDA-approved drug. Being discussed at PCAC, or named in a news story about an interim policy, is not a legal status.
Do not rely on a "research use only" disclaimer as cover. FDA's August warning letter to NuScience Peptides rejected that framing for products marketed as "research" peptides, and McDermott reports that dosing information, injection instructions and dose calculators were treated as evidence of intended human use.
Verify sourcing and documentation. If you do compound, confirm the exact substance, salt form, route, manufacturer, and certificates of analysis — and remember that state pharmacy law governs much of this at the day-to-day level.
Check your state board's position. According to McDermott, Alabama and Ohio have already issued guidance restricting research-grade peptides; other states may follow. State rules do not dissolve just because a federal policy loosens.
Review telehealth and referral agreements. If you prescribe for a telehealth or referral partner, ensure the contract lets you decline prescriptions and respond to a policy change without penalty.
Keep patient communication accurate. An interim policy, if one is issued, is not approval. Do not describe a compounded peptide as FDA-approved, clinically proven, or a generic equivalent.
Confirm with your licensing board and health-law counsel. This is the step that protects your license, not an optional formality.
If you are already running cash-pay service lines, the same compliance-first discipline applies here — we covered the enforcement pattern for IV therapy in our IV therapy compliance guide, and the underlying lesson (a state board or FDA action can change the risk profile of a service line overnight) carries straight over to peptides. For the business side of deciding whether a peptide line fits your practice, see our cash-pay and membership models guide.

Frequently asked questions
Are BPC-157 and the other five peptides legal to compound right now?
No. None has been added to the 503A Bulks List and none is FDA-approved. The July PCAC votes were advisory, and FDA has not issued a final rule.
What did the PCAC vote actually change?
Nothing by itself. The committee recommended six of seven peptides for possible 503A list placement, but a recommendation does not amend the list or authorize compounding.
Is the interim access policy in effect?
No. FDA submitted it to OIRA on October 14, 2026, and it is pending review. Its text, scope, and conditions have not been made public, and it has not been issued.
Is BPC-157 an FDA-approved drug?
No. BPC-157 is not FDA-approved for any indication. It is also classified as a doping substance by international sports authorities.
What did FDA's August warning letters say?
FDA told online peptide sellers that their "research use only" products were unapproved new drugs, that bacteriostatic water sold for injection is itself a drug, and that continued violations could lead to seizure or injunction.
Do state rules still apply if FDA loosens federal policy?
Yes. A federal enforcement policy does not override state pharmacy or medical board requirements. According to McDermott Will & Emery, Alabama and Ohio have already issued guidance restricting research-grade peptides.
What should I verify before prescribing or compounding a peptide?
Confirm the substance's legal status, sourcing and certificates of analysis, your state board's position, and the terms of any telehealth or referral agreement — and confirm all of it with health-law counsel.
The Bottom Line
FDA is signaling movement on peptide compounding — an advisory vote in July, an interim policy at the White House in October — but the legal status of these six peptides has not changed. None of the six is approved, none is on the bulks list, and enforcement against unapproved peptides is active. Treat the policy as a reason to prepare, not a reason to prescribe.
Ready to build a peptide line on the right side of the compliance line? The free peptide training covers how to approach peptides as a clinical service — safely and within your scope — rather than chasing headlines. Start the free peptide training.
This article is for educational purposes for licensed healthcare professionals and is not legal advice. Scope of practice and peptide compounding rules vary by state; confirm requirements with your licensing board and health-law counsel.
Sources
FDA — July 23–24, 2026 PCAC meeting — U.S. FDA
FDA Panel Backs 6 Peptides for Compounding — AJMC, July 2026
FDA Warning Letter — NuScience Peptides — U.S. FDA, August 2026
US FDA takes step to change peptide compounding policy — Reuters, October 2026
FDA Submits Interim Peptide Compounding Policy for White House Review — Buchanan Ingersoll & Rooney, October 2026
Hims & Hers to sell compounded peptides pending FDA approval — Becker's Hospital Review, August 2026
Federal regulators and state boards crack down on RUO peptides — McDermott Will & Emery, 2026
Doctors for America — statement on the interim policy — Doctors for America, October 2026